MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

MDT

95.62

+0.66%↑

VEEV

283

-3.27%↓

A

141.9

+0.66%↑

HQY

91.19

+0.35%↑

TLRY

1.55

+1.31%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Closed

3.29 -5.19

Overview

Share price change

24h

Current

Min

3.29

Max

3.35

Key metrics

By Trading Economics

Income

-17M

-70M

Sales

547K

47M

Profit margin

-147.345

Employees

560

EBITDA

-17M

-66M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+41.52% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

415M

1.2B

Previous open

8.48

Previous close

3.29

Technical Score

By Trading Central

Confidence

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Chart

Past performance is not a reliable indicator of future results.

Related News

17 Oct 2025, 18:13 UTC

Major Market Movers

Revolution Medicines Rises as FDA Grants Priority Designation for Cancer Treatment

17 Oct 2025, 17:05 UTC

Major Market Movers

Artiva Biotherapeutics Shares Jump After Treatment Gets Fast Tracked

18 Oct 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Deal Expected to Value Unit at Roughly $4B, Sources Say -- WSJ

18 Oct 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Deal Could Be Announced as Soon as Next Week, Sources Say -- WSJ

18 Oct 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Gucci Owner Kering Nears $4 Billion Sale of Beauty Unit to L'Oréal -- WSJ

18 Oct 2025, 13:30 UTC

Acquisitions, Mergers, Takeovers

Gucci Parent Kering in Talks to Sell Beauty Business to L'Oréal, Sources Say -- WSJ

18 Oct 2025, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

18 Oct 2025, 07:00 UTC

Earnings

A Growing Nimby Movement Could Upend the Data Center Boom -- Barrons.com

17 Oct 2025, 23:25 UTC

Acquisitions, Mergers, Takeovers

New Zealand's 'Golden Visa' Targets the Affluent in Search of Plan B -- Barrons.com

17 Oct 2025, 22:15 UTC

Market Talk

Ulta's CFO Appointment Seen Supporting Growth -- Market Talk

17 Oct 2025, 21:15 UTC

Market Talk

Greece Expected to Post Overall Budgetary Surplus This Year -- Market Talk

17 Oct 2025, 21:07 UTC

Market Talk

Oracle Stock Expected to Take a Breather as Capex Climbs -- Market Talk

17 Oct 2025, 21:07 UTC

Market Talk

Global Equities Roundup: Market Talk

17 Oct 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 Oct 2025, 20:34 UTC

Market Talk

Deere Is Reaching the End of Its Downcycle -- Market Talk

17 Oct 2025, 20:27 UTC

Market Talk

Soft Growth Ahead in Canada But Not Far Off From Potential GDP, Macklem Says -- Market Talk

17 Oct 2025, 19:46 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

17 Oct 2025, 19:45 UTC

Market Talk

Oil Futures Stabilize, But End Week With A Loss -- Market Talk

17 Oct 2025, 18:45 UTC

Market Talk

Treasury Yields, Dollar Try to Reclaim Some Ground -- Market Talk

17 Oct 2025, 17:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Oct 2025, 17:51 UTC

Market Talk

Euro Still a Long Way From Supplanting Dollar, Former ECB Rate Setter Says -- Market Talk

17 Oct 2025, 17:44 UTC

Market Talk

EQT Seen With Long-Term Growth Opportunities -- Market Talk

17 Oct 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Unchanged at 418 -- Market Talk

17 Oct 2025, 16:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

17 Oct 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 Oct 2025, 16:14 UTC

Market Talk

Home Depot Will Gain From Pick Up in Home Improvement Activity -- Market Talk

17 Oct 2025, 16:04 UTC

Market Talk

Home Improvement Demand Is Starting to Pick Up -- Market Talk

17 Oct 2025, 15:58 UTC

Market Talk

Amazon's Project Rainier Will Begin to Stem Its AI Share Losses -- Market Talk

17 Oct 2025, 15:56 UTC

Earnings

These Stocks Are Moving the Most Today: Zions Bancorp, Jefferies, Amex, Oracle, Novo Nordisk, Lilly, State Street, CSX, and More -- Barrons.com

17 Oct 2025, 15:43 UTC

Market Talk

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Maravai LifeSciences Holdings Inc (Class A) Forecast

Price Target

By TipRanks

41.52% upside

12 Months Forecast

Average 4.67 USD  41.52%

High 5 USD

Low 4 USD

Based on 6 Wall Street analysts offering 12 month price targets forMaravai LifeSciences Holdings Inc (Class A) - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

4

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

2.02 / 2.115Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat